Cancer of unknown primary: challenges and progress in clinical management

N Laprovitera, M Riefolo, E Ambrosini, C Klec… - Cancers, 2021 - mdpi.com
Simple Summary Patients with cancer of unknown primary site suffer the burden of an
uncertain disease, which is characterized by the impossibility to identify the tissue where the …

International consensus on the initial diagnostic workup of cancer of unknown primary

I van der Strate, F Kazemzadeh, ID Nagtegaal… - Critical Reviews in …, 2023 - Elsevier
Background Although the incidence of Cancer of Unknown Primary (CUP) is estimated to be
1–2% of all cancers worldwide, no international standards for diagnostic workup are yet …

[HTML][HTML] Molecular profiling of driver events in metastatic uveal melanoma

J Karlsson, LM Nilsson, S Mitra, S Alsén… - Nature …, 2020 - nature.com
Metastatic uveal melanoma is less well understood than its primary counterpart, has a
distinct biology compared to skin melanoma, and lacks effective treatments. Here we …

Treatment with anti-HER2 chimeric antigen receptor tumor-infiltrating lymphocytes (CAR-TILs) is safe and associated with antitumor efficacy in mice and companion …

EMV Forsberg, R Riise, S Saellström, J Karlsson… - Cancers, 2023 - mdpi.com
Simple Summary CAR-T cells are immune cells equipped with a claw that enable them to
bind cancer cells. Usually, CAR-T cells are made using immune cells from blood. Here, we …

[HTML][HTML] Development and clinical validation of a 90-gene expression assay for identifying tumor tissue origin

Q Ye, Q Wang, P Qi, J Chen, Y Sun, S Jin… - The Journal of Molecular …, 2020 - Elsevier
The accurate identification of tissue origin in patients with metastatic cancer is critical for
effective treatment selection but remains a challenge. The aim of this study is to develop a …

Machine learning for pan-cancer classification based on RNA sequencing data

P Štancl, R Karlić - Frontiers in molecular biosciences, 2023 - frontiersin.org
Despite recent improvements in cancer diagnostics, 2%-5% of all malignancies are still
cancers of unknown primary (CUP), for which the tissue-of-origin (TOO) cannot be …

Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and …

J Sheng, H Pan, W Han - Frontiers in Immunology, 2023 - frontiersin.org
Background Cancer of unknown primary (CUP) is a malignant and aggressive tumor whose
primary origin is still unknown despite thorough evaluation. CUP can be life-threatening with …

[HTML][HTML] Genetics and Therapeutic Responses to Tumor-Infiltrating Lymphocyte Therapy of Pancreatic Cancer Patient-Derived Xenograft Models

LM Nilsson, C Vilhav, JW Karlsson, JB Fagman… - Gastro Hep …, 2022 - Elsevier
Background and Aims Pancreatic cancer is the seventh leading cause of cancer-related
deaths worldwide. Checkpoint immunotherapy has not yet shown encouraging results in …

H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines

T Hofving, J Karlsson, O Nilsson, JA Nilsson - Nature Genetics, 2019 - nature.com
To the Editor—We read with great interest the recent paper1 by Alvarez et al. In it, they use
the VIPER algorithm2 to mine transcriptome data from 212 rare gastroentero-pancreatic …

Molecular profiling of driver events and tumor-infiltrating lymphocytes in metastatic uveal melanoma

J Karlsson, LM Nilsson, EMV Forsberg, S Mitra, S Alsén… - bioRxiv, 2019 - biorxiv.org
Uveal melanoma (UM) is a rare form of melanoma with a genetics and immunology that is
different from skin melanoma. Previous studies have identified genetic driver events of early …